Nurse Practitioner Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Aseel Abu-Nasser

Dermatology Redding, CA Nurse Practitioner

NPI 1609641711 CMS profile 11532438

375 Smile Pl Ste B, Redding, CA 96001

Open in the dashboard

General payments

$5,648

305 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Aseel Abu-Nasser of Redding, CA is reported in the CMS Open Payments database as having received $5,648 across 305 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,810 139
2024 General $2,516 146
2023 General $323 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aseel Abu-Nasser
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Aseel Abu-Nasser were reported at $2,810. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Aseel Abu-Nasser Dermatology median Middle half National median
2019 $0 $454 $129–$1,240 $163
2020 $0 $235 $81–$756 $114
2021 $0 $377 $108–$1,108 $132
2022 $0 $514 $143–$1,391 $149
2023 $323 $607 $159–$1,674 $160
2024 $2,516 $751 $204–$1,903 $164
2025 $2,810 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. AbbVie, Inc. $1,401 112 payments
  2. Genzyme Corporation $684 26 payments
  3. Lilly USA, LLC $561 27 payments
  4. Regeneron Healthcare Solutions, Inc. $549 30 payments
  5. UCB, Inc. $351 21 payments
  6. Incyte Corporation $335 14 payments
  7. Novartis Pharmaceuticals Corporation $268 12 payments
  8. LEO Pharma Inc. $240 10 payments
  9. Janssen Biotech, Inc. $233 17 payments
  10. Galderma Laboratories, L.P. $208 3 payments
  11. Other $819 33 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $5,484 302 payments
  2. Education $164 3 payments
Products named General payments · program years 2023–2025
  1. DUPIXENT Immunology $805 33 payments
  2. RINVOQ $647 43 payments
  3. TALTZ $561 27 payments
  4. SKYRIZI $518 46 payments
  5. DUPIXENT Inflammation And Immunology $382 16 payments
  6. Bimzelx $351 21 payments
  7. VTAMA $348 12 payments
  8. EBGLYSS $339 15 payments
  9. OPZELURA $335 14 payments
  10. TREMFYA $233 17 payments
  11. Other $1,717 94 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

305 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record